Compare Summit Therapeutics Inc (SMMT) vs Ulta Beauty Inc (ULTA) Price & Performance

Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.

The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.

ULTA trades at $564.21, up 3.43% today, with a bullish technical outlook and strong institutional support. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 guidance, driven by e-commerce momentum. Valuation metrics show a P/E of 20.55 and P/S of 1.92, while profitability remains robust with a 9.34% net income margin and 46.12% ROE.

The stock offers growth potential with a consensus price target of $624.93, but faces risks from margin pressure and flat store traffic. Execution on raised guidance and expansion into wellness categories are key catalysts, though consumer spending volatility and promotional intensity could limit upside.